Samsara Inc vs Revvity Inc — how do they compare? Samsara Inc trades at $41.53 (market cap $24.14B), while Revvity Inc trades at $154.1 (market cap $16.98B). The key difference: Samsara Inc is the larger of the two by market cap, and Revvity Inc pays a 0.18% dividend while Samsara Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Samsara Inc for 19 Days and Revvity Inc for 12 Days on average.
| IOT | RVTY | |
|---|---|---|
Market Cap | $24.14B | $16.98B |
Volume | 5,372,580 | 1,456,900 |
Sector | Technology | Health |
52-Week High | $45.22 | $157.36 |
52-Week Low | $24.25 | $82.26 |
Typical Hold Time | 19 Days | 12 Days |
Enterprise Value | $23.38B | $19.30B |
Dividend Yield | — | 0.18% |
Signals from Pluang's Aura AI — not financial advice
Samsara Inc. (IOT) trades at $41.61, up 2.72% today, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $0.20 exceeding the $0.16 forecast. Revenue growth is robust, projected to rise from $1.25 billion in 2025 to $1.8 billion in 2026, while the company transitions to profitability with a net margin of 4.9% in 2026. Recent partnerships and product launches, like the Laval Rocket sponsorship and Samsara MCP, highlight ongoing business expansion.
The investment outlook is positive, driven by earnings beats, revenue acceleration, and a consensus price target of $51.15 implying 23% upside. However, high valuation multiples (P/E of 274.8, P/S of 13.01) pose risks if growth slows. Cash flow pressures in 2026 and insider selling are additional concerns. The stock's momentum depends on sustaining its growth trajectory amid competitive and execution risks.
RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.
The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Samsara provides a connected operations cloud that uses IoT data to help businesses improve efficiency and safety. Its platform offers real-time visibility for fleet management, equipment monitoring, and industrial sites.
Read more on IOT →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →